"versionIdentifier","uuid:ID","instanceType","rationale","id"
"2","6685cbab-2a56-4f57-9855-06b9161119b9","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
